Cysteine Aids Mice with Huntington’s

Rodent models of Huntington’s disease show dysfunctional cysteine production, and adding the amino acid to their diets seems to relieve symptoms.  

By | March 31, 2014

WIKIMEDIA, DR. STEVEN FINKBEINER

Scientists recently reported new insights into a possible molecular mechanism of Huntington’s disease and offered a potential route to correcting it. Experiments on mouse models of the neurodegenerative disease pointed to a dysfunction in the biosynthesis of the amino acid cysteine, and showed that supplementing their diets with cysteine seemed to reverse signs of the disease, according to a team led by researchers at the Johns Hopkins University School of Medicine. Their work was published in Nature last week (March 26).

“This is a very plausible theory (it seems to me), and the paper makes a very strong case for it,” Derek Lowe wrote at his blog, In The Pipeline.

Huntington’s researchers have long known the genetic culprit of the disease—a string of glutamines at the end of a gene encoding the protein huntington—yet it remains incurable. Johns Hopkins’s Solomon Snyder and his colleagues now propose that the function of an enzyme involved in cysteine production, cystathionine gamma-lyase (CSE), also goes awry. But supplementing the diets of affected mice with cysteine improved survival and appeared to slow the disease, the team reported.

Snyder urged caution in taking the findings too far. “Since the disease is based on a very discrete genetic abnormality, the mouse model is very good,” Snyder told Chemical & Engineering News. “But it makes me nervous to get people’s hopes up. We won’t know if this is a successful therapy until it is tested in clinical trials.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham